TY - JOUR
T1 - Molecular insights of CREB and MAP-K phosphorylation by modafinil in wake-related brain areas
AU - Jiménez-Moreno, Ramsés
AU - Farret-Ramos, Adrián A.
AU - Valle-Ayala, Adriana
AU - Trujillo-Paredes, Niurka
AU - Murillo-Rodríguez, Eric
N1 - Publisher Copyright:
© 2018 Bentham Science Publishers.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Background: Modafinil (MOD) is a waking-promoting compound that is used for the treatment of sleep disorders such as sleepiness and narcolepsy. Despite its efficiency, there are missing pieces of evidence regarding the mechanism of action of MOD at molecular level. For example, current data have demonstrated that MOD induces alertness by activating several wake-related neurotransmitter receptors, including dopamine 1 (D1) receptor. Nevertheless, an intriguing point highlights that MOD might be activating intracellular elements bounded to D1 receptor, such as cAMP response element-binding (CREB) or mitogen-activated protein kinase (MAP-K) expression. Objective: We tested whether administrations of MOD induce phosphorylation of either CREB or MAP-K in wake-related brain areas, such as dorsomedial hypothalamic nucleus (DM) and tuberomammillary nucleus (TMN) in rats. Methods: Rats that received a systemic injection of MOD (30 or 150 mg/Kg) were sacrificed and brains were processed for immunohistochemical analysis of phospho-CREB or phospho-MAP-K staining. Results: MOD dose-dependently enhanced phospho-CREB and phospho-MAP-K immunoreactivity in DM and TMN. Moreover, the statistical analysis revealed that MOD increased the number of phospho-CREB and phospho-MAP-K immunoreactive neurons in these brain areas studied. Conclusion: These findings provide significative insights regarding the possible molecular mechanism of action of MOD engaging the activation of phospho-CREB and phospho-MAP-K in wake-linked brain areas. Indeed, further studies are required to fully understand the molecular mechanism of action of MOD.
AB - Background: Modafinil (MOD) is a waking-promoting compound that is used for the treatment of sleep disorders such as sleepiness and narcolepsy. Despite its efficiency, there are missing pieces of evidence regarding the mechanism of action of MOD at molecular level. For example, current data have demonstrated that MOD induces alertness by activating several wake-related neurotransmitter receptors, including dopamine 1 (D1) receptor. Nevertheless, an intriguing point highlights that MOD might be activating intracellular elements bounded to D1 receptor, such as cAMP response element-binding (CREB) or mitogen-activated protein kinase (MAP-K) expression. Objective: We tested whether administrations of MOD induce phosphorylation of either CREB or MAP-K in wake-related brain areas, such as dorsomedial hypothalamic nucleus (DM) and tuberomammillary nucleus (TMN) in rats. Methods: Rats that received a systemic injection of MOD (30 or 150 mg/Kg) were sacrificed and brains were processed for immunohistochemical analysis of phospho-CREB or phospho-MAP-K staining. Results: MOD dose-dependently enhanced phospho-CREB and phospho-MAP-K immunoreactivity in DM and TMN. Moreover, the statistical analysis revealed that MOD increased the number of phospho-CREB and phospho-MAP-K immunoreactive neurons in these brain areas studied. Conclusion: These findings provide significative insights regarding the possible molecular mechanism of action of MOD engaging the activation of phospho-CREB and phospho-MAP-K in wake-linked brain areas. Indeed, further studies are required to fully understand the molecular mechanism of action of MOD.
KW - Hypothalamus
KW - Immunohistochemistry
KW - Modafinil
KW - Tuberomammillary nucleus
KW - Waking
UR - http://www.scopus.com/inward/record.url?scp=85046708030&partnerID=8YFLogxK
U2 - 10.2174/1874467209666161214152006
DO - 10.2174/1874467209666161214152006
M3 - Artículo
C2 - 27981901
AN - SCOPUS:85046708030
SN - 1874-4672
VL - 11
SP - 140
EP - 148
JO - Current Molecular Pharmacology
JF - Current Molecular Pharmacology
IS - 2
ER -